Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
2004 1
2009 1
2011 1
2013 1
2014 1
2015 2
2016 2
2017 4
2018 3
2019 6
2020 3
2021 6
2022 6
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Results by year

Filters applied: . Clear all
Page 1
KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer.
Kato K, Shah MA, Enzinger P, Bennouna J, Shen L, Adenis A, Sun JM, Cho BC, Özgüroğlu M, Kojima T, Kostorov V, Hierro C, Zhu Y, McLean LA, Shah S, Doi T. Kato K, et al. Among authors: hierro c. Future Oncol. 2019 Apr;15(10):1057-1066. doi: 10.2217/fon-2018-0609. Epub 2019 Feb 8. Future Oncol. 2019. PMID: 30735435 Free article. Clinical Trial.
Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study.
Meric-Bernstam F, Bahleda R, Hierro C, Sanson M, Bridgewater J, Arkenau HT, Tran B, Kelley RK, Park JO, Javle M, He Y, Benhadji KA, Goyal L. Meric-Bernstam F, et al. Among authors: hierro c. Cancer Discov. 2022 Feb;12(2):402-415. doi: 10.1158/2159-8290.CD-21-0697. Epub 2021 Sep 22. Cancer Discov. 2022. PMID: 34551969 Free PMC article. Clinical Trial.
Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study.
Gazzah A, Bedard PL, Hierro C, Kang YK, Abdul Razak A, Ryu MH, Demers B, Fagniez N, Henry C, Hospitel M, Soria JC, Tabernero J. Gazzah A, et al. Among authors: hierro c. Ann Oncol. 2022 Apr;33(4):416-425. doi: 10.1016/j.annonc.2021.12.012. Epub 2022 Jan 10. Ann Oncol. 2022. PMID: 35026412 Free article. Clinical Trial.
Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors.
Bahleda R, Italiano A, Hierro C, Mita A, Cervantes A, Chan N, Awad M, Calvo E, Moreno V, Govindan R, Spira A, Gonzalez M, Zhong B, Santiago-Walker A, Poggesi I, Parekh T, Xie H, Infante J, Tabernero J. Bahleda R, et al. Among authors: hierro c. Clin Cancer Res. 2019 Aug 15;25(16):4888-4897. doi: 10.1158/1078-0432.CCR-18-3334. Epub 2019 May 14. Clin Cancer Res. 2019. PMID: 31088831 Clinical Trial.
The expanding role of immunotherapy.
Martin-Liberal J, Ochoa de Olza M, Hierro C, Gros A, Rodon J, Tabernero J. Martin-Liberal J, et al. Among authors: hierro c. Cancer Treat Rev. 2017 Mar;54:74-86. doi: 10.1016/j.ctrv.2017.01.008. Epub 2017 Feb 11. Cancer Treat Rev. 2017. PMID: 28231560 Review.
Antiangiogenic therapies in gastric cancer: trusting the pathway.
Alsina M, Hierro C, Tabernero J. Alsina M, et al. Among authors: hierro c. Ann Oncol. 2016 Dec;27(12):2141-2143. doi: 10.1093/annonc/mdw541. Epub 2016 Oct 13. Ann Oncol. 2016. PMID: 27742655 Free article. No abstract available.
38 results